The NMPA Approves Innovent Biologics’ Dupert (Fulzerasib) to Treat NSCLC
Shots:
- The NMPA has approved Dupert (KRAS G12C Inhibitor) to treat individuals with advanced NSCLC who carry the KRAS G12C mutation and have undergone at least 1 therapy
- The approval was based on the P-II trial that assessed the efficacy & safety of fulzerasib monotx. as a treatment for NSCLC individuals (n=116) with KRAS G12C mutation, who have either not responded to or could not tolerate standard therapy
- The result of Fulzerasib was ORR (49.1%) evaluated by the IRRC, DCR (90.5%), mPFS (9.7mos.), and mDoR & mOS not been reached. This data was published in the JTO
Ref: Innovent | Image: Innovent
Related News:- Innovent Reports the NMPA’s NDA Acceptance of Mazdutide to Treat Type 2 Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com